Please login to the form below

Not currently logged in
Email:
Password:

Revolution Medicines appoints Dr Stephen Kelsey

He joins the firm from Onkaido Therapeutics

Dr Stephen KelseyRevolution Medicines has appointed Dr Stephen Kelsey as its senior leader in a role that will see him focus on advancing medical agendas to aid cancer patients.

Most recently president at Onkaido Therapeutics, Kelsey’s specialty lies within oncology and development.

He said: “Revolution Medicines uses a novel approach to drug discovery that enables it to tackle promising cancer targets that have been difficult to access by convention means.

“I’m impressed with the quality of the company’s research team, founders and advisors, and am keen to help bring the next generation of transformational therapeutics to cancer patients.”

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.

Mark Goldsmith, president and chief executive officer of Revolution Medicines, said: “Steve has had a distinguished career in oncology as both an academic clinician and a drug development executive in the biotechnology industry.

“He is superbly positioned to help us by deliver great benefit to cancer patients by advancing our lead programmes and creating a sustainable product pipeline that harnesses frontier oncology targets.”

31st March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics